The novel 52 benzodipyranone analogs were synthesized and evaluated for their P-gp inhibitory activity.
Compound5a can enable the increase of the intracellular accumulation of P-gp substrate Calcein-AM.
Compound5a exhibited more potency on promoted anticancer drugs cytotoxicity by reversing P-gp-mediated drug resistance.
Compound5a can enhance the sensitization of resistant cell lines toward paclitaxel, vincristine, and doxorubicin.